Emergent to make Calgary-based Providence Therapeutics’ potential COVID-19 vaccine


COVID Vaccine Providence 20210126

Emergent BioSolutions Inc. spurred a five-year agreement with Calgary-based biotechnology company Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate for about $90 million.

Leave a Reply

Your email address will not be published. Required fields are marked *